Phase 2 N=35 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Primary: Complete Response Rate — 21; 9; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=399 A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
COVID-19
Primary: COVID-19 Prophylaxis — 30; 105 Participants
Phase 2 N=18 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Phase 2 N=22 Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery
Liver Cancer
Primary: Median Overall Survival — 31.1 months
Phase 2 N=40 High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Phase 2 N=81 Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Progression Free Survival (rPFS) — 6.4; 14.8 months
Phase 2 N=103 ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Phase 2 N=1 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID 19 · SARS-CoV 2 · Pneumonia
Primary: Proportion of Subjects Alive and Off Oxygen at 14 Days — 1; 0 Participants
Phase 2 N=486 Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer
Metastatic Breast Cancer
Primary: 1-year Progression Free Survival — 79.4; 77.9 percentage of participants
Phase 2 N=14 Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
ALS
Primary: Dose Limiting Toxicities (DLT) — 1; 2 Participants
Phase 2 N=122 Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
Metastatic Breast Cancer · Breast Carcinoma
Primary: Progression Free Survival (PFS) — 2.76; 5.29 months
Phase 2 N=17 A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Change in Area Under the Concentration-time Curve From Time Zero to Infinity (AUC[0-infinity]) of Each of the 5 Probe Drugs Before and After 9-week Nemolizumab Treatment…
Phase 2 N=18 Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension
Hypertension · Pulmonary Arterial Hypertension · Familial Primary Pulmonary Hypertension
Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm
Phase 2 N=57 Thromboxane Receptor Antagonist to Improve Endothelial Function
Cardiovascular Diseases · Vascular Dilation
Primary: Change in Reactive Hyperemia Index (RHI) — -0.01; 0.21 percentage index change
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants